The Value of 68Ga-grazytracer PET in Monitoring Responses to Immunotherapy of Pancreatic Cancer.

Recruiting now

Conditions studied: Pancreatic Cancer

In brief

This study aims to investigate the value of 68Ga-grazytracer in predicting the efficacy of immunotherapy for pancreatic cancer.

Key facts

Study ID

NCT06601010

Run by

Ruijin Hospital

People needed

30

Starts

2024-09-24

Expected to finish

2027-08-31

Last updated by the study team

2024-12-11

Who can join

Age: 18 and older, up to 75. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Pathological diagnosis of pancreatic cancer requiring combination immunotherapy after evaluation according to clinical guidelines
• Signed and dated informed consent form
• Commitment to comply with research procedures and co-operation in the implementation of the full research process 4 .aged 18-75 years old 5 .The patient is in good general condition with an expected survival of \> 6 months

You may not qualify if…

• Patients with serious illnesses that researchers consider unsuitable for participation in this clinical study. Such as severe heart and lung failure, severe bone marrow suppression, severe liver and kidney dysfunction, etc.
• Intestinal perforation, complete intestinal obstruction
• Pregnant women and women who may be pregnant, women who are breastfeeding.
• Non-compliant person

Where it is running

• Ruijin Hospital affiliated to Shanghai Jiao Tong University of Medicine — Shanghai, Shanghai Municipality, China (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.